Cargando…

Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL

Acute myeloid leukemia (AML) and B-cell acute lymphocytic leukemia (B-ALL) are severe blood malignancies affecting both adults and children. Chimeric antigen receptor (CAR)-based immunotherapies have proven highly efficacious in the treatment of leukemia. However, the challenge of the immune escape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ureña-Bailén, Guillermo, Dobrowolski, Jérôme-Maurice, Hou, Yujuan, Dirlam, Alicia, Roig-Merino, Alicia, Schleicher, Sabine, Atar, Daniel, Seitz, Christian, Feucht, Judith, Antony, Justin S., Mohammadian Gol, Tahereh, Handgretinger, Rupert, Mezger, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655234/ https://www.ncbi.nlm.nih.gov/pubmed/36361619 http://dx.doi.org/10.3390/ijms232112828

Ejemplares similares

CRISPR medicine for blood disorders: Progress and challenges in delivery
por: Mohammadian Gol, Tahereh, et al.
Publicado: (2023)

In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment
por: Grote, Stefan, et al.
Publicado: (2021)

Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing
por: Hou, Yujuan, et al.
Publicado: (2022)

CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells
por: Mohammadian Gol, Tahereh, et al.
Publicado: (2023)

Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting
por: Grote, Stefan, et al.
Publicado: (2020)

Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases
por: Grote, Stefan, et al.
Publicado: (2021)

NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
por: Schlegel, Patrick, et al.
Publicado: (2015)

Somatic Reversion of a Novel IL2RG Mutation Resulting in Atypical X-Linked Combined Immunodeficiency
por: Hou, Yujuan, et al.
Publicado: (2021)

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2020)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia
por: Pfeiffer, Matthias Manuel, et al.
Publicado: (2013)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
por: Roex, Gils, et al.
Publicado: (2022)

Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation
por: Döring, Michaela, et al.
Publicado: (2015)

Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells
por: Panwong, Suthida, et al.
Publicado: (2021)

Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML
por: Kent, Andrew, et al.
Publicado: (2023)

P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
por: Huang, Ruihao, et al.
Publicado: (2023)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Depletion of Akt1 and Akt2 Impairs the Repair of Radiation-Induced DNA Double Strand Breaks via Homologous Recombination
por: Mohammadian Gol, Tahereh, et al.
Publicado: (2019)

Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem Cell Transplantations for Acute Lymphoblastic Leukemia
por: Döring, Michaela, et al.
Publicado: (2012)

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
por: Klingemann, H
Publicado: (2014)

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
por: Klingemann, Hans, et al.
Publicado: (2016)

Limited response of NK92 cells to Plasmodium falciparum-infected erythrocytes
por: de Carvalho, Elisandra Grangeiro, et al.
Publicado: (2011)

Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors
por: Yang, Chaopin, et al.
Publicado: (2019)

Efficient delivery of oncolytic enterovirus by carrier cell line NK-92
por: Podshivalova, Elizaveta Sergeevna, et al.
Publicado: (2021)

Corrigendum: Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors
por: Yang, Chaopin, et al.
Publicado: (2019)

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
por: Chrobok, Michael, et al.
Publicado: (2019)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity
por: Shin, Hyun Young, et al.
Publicado: (2023)

Repression of GSK3 restores NK cell cytotoxicity in AML patients
por: Parameswaran, Reshmi, et al.
Publicado: (2016)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
por: Cutmore, Lauren C., et al.
Publicado: (2021)

Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy
por: Klose, Chihab, et al.
Publicado: (2019)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Detection of Active Granzyme A in NK92 Cells with Fluorescent Activity-Based Probe
por: Kołt, Sonia, et al.
Publicado: (2020)

Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins
por: Huang, Rih-Sheng, et al.
Publicado: (2020)

Natural Killer Cell Line NK-92-Mediated Damage of Medically Important Fungi
por: Schmidt, Stanislaw, et al.
Publicado: (2021)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ecjle3lvvh7tomfavd7dmlh0fr